Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics has secured an expansion of its agreement with WellStreet Urgent Care to roll out its FebriDx rapid point-of-care test across 43 additional locations in Georgia and Michigan, following a successful pilot at a single Piedmont Healthcare joint-venture site. This move leverages the recent U.S. CLIA waiver for FebriDx and will see the test offered under a standing order to every patient with acute respiratory infection symptoms, with results available before clinicians enter the exam room.
The expanded program, embedded into WellStreet’s clinical workflow, positions FebriDx as a standard tool in evaluating respiratory illness across a network handling about 1.1 million acute respiratory cases annually. Lumos expects the increased testing volume and enhanced payor visibility to support a full rollout to all 163 WellStreet locations within 6–12 months, strengthening its bargaining power in future contracts and potentially setting a new benchmark for urgent care diagnostics and antibiotic stewardship.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is an Australia-based developer of rapid, point-of-care diagnostic technologies, including its FebriDx test used to assess acute respiratory infections. The company targets urgent care and similar healthcare providers, aiming to improve clinical decision-making speed, antibiotic stewardship, and reimbursement outcomes in the U.S. market and other key geographies.
Average Trading Volume: 4,837,410
Technical Sentiment Signal: Hold
Current Market Cap: A$161.5M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.